Inivata’s InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Inivata was acquired by NeoGenomics in 2021 for $390 million.


Cambridge, UK


Acquired by NeoGenomics in 2021 for $390 million

Related companies